Corgi Genomics & Precision Medicine ETF
GNMX - ETF AI Analysis
Top Page
Corgi Genomics & Precision Medicine ETF (GNMX)
GNMX, the Corgi Genomics & Precision Medicine ETF, is supported by several high-quality holdings like Incyte, Vertex Pharmaceuticals, Genmab, Thermo Fisher, and Illumina, which show strong financial performance, solid growth prospects, and generally positive long-term outlooks. However, weaker holdings such as Iovance Biotherapeutics and Revolution Medicines, which face ongoing losses, cash flow issues, and bearish trends, weigh on the fund’s overall quality. The main risk factor is the ETF’s focus on genomics and biotech, a sector where many companies have volatile earnings, high valuations, and significant uncertainty around future profitability.
GNMX vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.24M
- Region
- Global
- Expense Ratio
- 0.35%
- Beta
- 0.58
- Issuer
- Corgi
- Inception Date
- May 06, 2026
- Dividend Yield
- N/A
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
GNMX Summary
The Corgi Genomics & Precision Medicine ETF (GNMX) is a healthcare-focused fund that invests in companies using DNA and data to develop new tests and treatments. It follows a genomics and precision medicine theme rather than a broad market index, holding firms involved in gene editing, cancer therapies, and advanced diagnostics. Well-known names in the fund include Thermo Fisher and Moderna. Someone might invest in GNMX for long-term growth and to tap into cutting-edge medical innovation. However, because it is heavily focused on genomics and biotech, its price can be very volatile and may swing more than the overall market.
How much will it cost me?
This ETF has an expense ratio of 0.35%, which means you’ll pay about $3.50 per year for every $1,000 you invest. That’s higher than the cost of a typical broad, passively managed index ETF because this is a specialized, actively managed fund focused on genomics and precision medicine companies.
What would affect this ETF?
This genomics and precision medicine ETF could benefit if new DNA-based tests and targeted treatments from companies like Thermo Fisher, Vertex, and Moderna gain wider medical acceptance, if healthcare systems increase spending on advanced diagnostics, and if supportive drug-approval policies encourage innovation globally. On the other hand, it could be hurt by tighter drug pricing rules, clinical trial setbacks at smaller biotech holdings, shifts in healthcare budgets away from high-cost therapies, or market pullbacks that hit high-growth health care stocks especially hard.
GNMX Top 10 Holdings
GNMX is leaning heavily into cutting-edge biotech, with Moderna and Iovance acting as key engines of recent gains as their pipelines and momentum stay firmly in the “rising” camp. Illumina and Thermo Fisher provide a steadier backbone, benefiting from demand for sequencing tools and lab equipment. On the weaker side, Guardant Health and 10x Genomics have been more mixed, occasionally dragging on performance as investors wrestle with their profitability and growth narratives. The fund is overwhelmingly health care–focused and globally diversified, but thematically concentrated in genomics and precision medicine.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Moderna | 11.28% | $144.49K | $93.61B | 794.91% | 59Neutral | |
| Thermo Fisher | 9.42% | $120.58K | $259.15B | 20.70% | 72Outperform | |
| Vertex Pharmaceuticals | 6.28% | $80.41K | $137.57B | 23.95% | 78Outperform | |
| Genmab | 4.48% | $57.32K | $31.11B | 69.87% | 76Outperform | |
| Illumina | 3.84% | $49.19K | $31.68B | 72.61% | 71Outperform | |
| Guardant Health | 3.30% | $42.25K | $20.95B | 61.16% | 61Neutral | |
| Revolution Medicines | 3.06% | $39.21K | $38.14B | 167.61% | 52Neutral | |
| Incyte | 2.81% | $35.95K | $24.81B | 14.76% | 81Outperform | |
| 10x Genomics | 2.75% | $35.18K | $7.77B | 255.90% | 60Neutral |
GNMX Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For GNMX, the sentiment is Negative. The current price of 34.94 is below the 20-day moving average (MA) of 37.11, below the 50-day MA of 36.76, and compared to the 200-day MA of , indicating a neutral trend. The MACD of -0.25 indicates Positive momentum. The RSI at 42.11 is Neutral, neither overbought nor oversold. The STOCH value of 14.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GNMX.
GNMX Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| $34.94 | $37.00(5.88% Upside) | $1.24M | 0.35% | 60Neutral | |
| $31.35 | $37.99(21.19% Upside) | $94.32M | 0.98% | 65Neutral | |
| $50.33 | $64.33(27.84% Upside) | $81.09M | 0.50% | 70Neutral | |
| $87.79 | $134.44(53.14% Upside) | $72.24M | 0.50% | 69Neutral | |
| $48.23 | $87.27(80.96% Upside) | $62.91M | 0.90% | 64Neutral | |
| $42.51 | $54.50(28.20% Upside) | $34.34M | 0.50% | 62Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GNMX | Corgi Genomics & Precision Medicine ETF | 34.94 | 9.24 | 35.94% | |
| FFND | Future Fund Active ETF | 31.35 | 2.05 | 7.01% | |
| FDCF | Fidelity Disruptive Communications ETF | 50.33 | 4.24 | 9.19% | |
| IQM | Franklin Intelligent Machines ETF | 87.79 | 2.89 | 3.40% | |
| HECO | SPDR Galaxy Hedged Digital Asset Ecosystem ETF | 48.23 | 7.88 | 19.54% | |
| HELX | Franklin Genomic Advancements ETF | 42.51 | 7.66 | 21.98% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
